

Tiziana Pressiani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/918428/publications.pdf>

Version: 2024-02-01

16
papers

3,016
citations

840119

11
h-index

940134

16
g-index

16
all docs

16
docs citations

16
times ranked

4002
citing authors

#	ARTICLE	IF	CITATIONS
1	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 401-413.	1.9	9
2	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435.	1.9	3
3	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	4.2	31
4	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
5	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. <i>Current Opinion in Oncology</i> , 2021, 33, 386-394.	1.1	13
6	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. <i>Drugs and Aging</i> , 2021, 38, 579-591.	1.3	5
7	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 927-939.	1.1	9
8	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	1.3	42
9	Tumor-Derived Prostaglandin E2 Promotes p50 NF- κ B-Dependent Differentiation of Monocytic MDSCs. <i>Cancer Research</i> , 2020, 80, 2874-2888.	0.4	81
10	Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 20-28.	3.4	159
11	<p>Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 31-39.	1.8	55
12	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 1938-1951.	0.4	58
13	Targeted agents for second-line treatment of advanced hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 788-803.	0.8	8
14	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	13.9	1,677
15	Regorafenib for the treatment of unresectable hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 567-576.	1.1	26
16	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 101-107.	1.8	191